Here are the top stories from the last week:

Industry Updates

HHS announces removal of thimerosal from all US flu vaccines
CDC's ACIP recommends removing thimerosal from flu vaccines, igniting debate on vaccine safety and fueling antivaccine sentiments amid public health concerns.
Read article »

Diligent Robotics reaches milestone in U.S. adoption of hospital pharmacy robotics
The company’s Moxi robots have completed over 300,000 pharmacy deliveries, enhancing hospital workflows. The robots are transforming hospital pharmacy operations by improving medication delivery, handling high-risk medications, and providing real-time accountability.
Read article »

GoodRx research maps scope of healthcare deserts
A new report from GoodRx reveals that healthcare deserts, including pharmacy deserts, have expanded in the U.S., affecting access to essential services for millions.
Read article »

Pharmacists can educate patients about sun safety
Particularly during summer months, counsel patients about sunscreen recommendations and drug-induced photosensitivity prevention strategies.
Read article »

NACDS applauds Senate action to ensure seniors on Medicare have access to certain state-approved pharmacist services
Bipartisan bill stands to enhance healthcare delivery for seniors nationwide, especially those in communities where provider shortages persist.
Read article »

UnitedHealth Group discloses DOJ investigation into Medicare billing practices
The company emphasized it has “full confidence in its practices” and is “committed to working cooperatively” with federal investigators.
Read article »

Roche considers direct-to-patient sales in U.S. amid earnings beat
The Swiss drugmaker is in active discussions with the U.S. government regarding a plan that could eliminate middlemen, such as pharmacy benefit managers (PBMs).
Read article »

Drug, Technology & Treatment Updates

Oveporexton demonstrates statistically significant, clinically meaningful improvements in patients with NT1
In 2 clinical trials, oveporexton shows promise in treating narcolepsy type 1 (NT1), paving the way for potential FDA approval.
Read article »

IBI303, Humira biosimilar, shows comparable efficacy and cost benefit to reference product
There were also no observed differences in retention rates or safety among patients with ankylosing spondylitis.
Read article »

‍